At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
FP-025 capsules +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses, Airway Inflammation and Aspects of Airway Remodeling in Subjects With Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma (HDM)-Allergic Asthma
In Brief
A Phase 2 clinical trial evaluating FP-025 capsules and Placebo FP-025 capsules for Asthma, COPD. Completed, enrolled 27 participants across 2 sites.
Detailed Summary
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, COPD
CountriesNetherlands
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJul 2018
First PostedMar 2019
Primary CompletionDec 2022
TodayJul 2026
First PostedMar 1, 2019
Enrollment StartJul 2, 2018
Primary CompletionDec 30, 2022
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 7.3 years ago
Interventions
FP-025 capsulesdrug
FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
Placebo FP-025 capsulesdrug
Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.